Edition:
India

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

477.10INR
1 Dec 2020
Change (% chg)

-- (--)
Prev Close
Rs477.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,377,683
52-wk High
Rs573.05
52-wk Low
Rs161.65

Summary

Name Age Since Current Position

Glenn Saldanha

50 2011 Executive Chairman of the Board, Chief Executive Officer, Managing Director

V. S. Mani

2018 Global Chief Financial Officer, Executive Director

Harish Kuber

2017 Compliance Officer, Company Secretary

Cherylann Pinto

Executive Director - Corporate Services

Blanche Saldanha

2005 Non-Executive Director

Dipankar Bhattacharjee

57 2020 Additional Independent Director

Rajesh Desai

52 2020 Independent Director

Sridhar Gorthi

48 2005 Non-Executive Independent Director

Devendra Mehta

83 2009 Non-Executive Independent Director

Bernard Munos

2012 Non-Executive Independent Director

Sona Ramasastry

2019 Non-Executive Independent Director

Brian Tempest

2012 Non-Executive Independent Director

Biographies

Name Description

Glenn Saldanha

Mr. Glenn Mario Saldanha serves as Executive Chairman of the Board, Chief Executive Officer, Managing Director of the Company. Mr. Saldanha joined Glenmark in 1998 as Director and took over as Managing Director and CEO in 2000. He transformed Glenmark into a truly global organization with revenues of over $1.5 billion (US). Under his leadership, Glenmark has evolved from an Indianbranded generics business into a research-driven and innovationled organization. Mr. Saldanha’s vision is to discover, develop and introduce India’s first innovative drug for the world.

V. S. Mani

Mr. V. S. Mani serves as Global Chief Financial Officer, Executive Director of the Company. Mr. Mani leads the organization’s worldwide finance operations and secretarial function, including global accounting, financial reporting, tax and treasury. He has over 29 years of rich industry experience across treasury, taxation, accounting, financial planning and analysis, secretarial, legal, audits, risk management and investor relations. Prior to joining Glenmark in 2017, he was the President, Finance at the Bhartiya Group. He has also held the position of the Chief Financial Officer at Cipla.

Harish Kuber

Cherylann Pinto

Mrs. Cherylann Pinto serves as Executive Director - Corporate Services of the Company. Mrs. Pinto has been the Director of Corporate Affairs at Glenmark since October 1999 and is an executive member of the Board. With over 30 years of experience in the pharmaceutical field, she currently heads the company’s Corporate services, Insurance, IT, Admin, HR and CSR functions. She had set up a pharmaceutical company where she served as the Managing Director from 1989 to 1999 before joining Glenmark.

Blanche Saldanha

Mrs. Blanche E. Saldanha serves as Non-Executive Director of Glenmark Pharmaceuticals Ltd. Mrs. Saldanha is a Non-Executive Director and a member of the promoter group of Glenmark. Prior to this, she was the Director for Exports and managed Glenmark’s international operations from 1982 to 2005. During her 23-year tenure with the organization, she was responsible for developing and growing the company’s export business.

Dipankar Bhattacharjee

Mr. Dipankar Bhattacharjee serves as Additional Independent Director of the Company. Mr. Dipankar Bhattacharjee has over 30 years of global experience in leading Generics, Specialty and OTC Pharma, Medical Devices, and FMCG businesses. Mr. Dipankar have led high performing teams to develop and execute business strategies across all stages of business cycles, driving growth and value through commercial innovation and focused R&D investments. Mr. Dipankar was associated with Teva group from 2009 to 2017. In his recent stint with Teva, he was President & CEO - Global Generics Medicines, Officer and Member of Teva Executive Committee (TEC). He played major role during his tenure with Teva as President & CEO of Teva Europe Generics; Senior Vice President of Teva Western Europe; Chief Executive Officer of Teva UK Ltd. Prior to Teva he had worked with Bausch & Lomb & Bank of America. Mr. Dipankar has Bachelors degree in Economics from University of Delhi, India and has .also done Master of Management Studies from Jamnalal Bajaj Institute of Management Studies, University of Bombay, India.

Rajesh Desai

Mr. Rajesh V. Desai serves as Independent Director of the Company. Mr. Desai is a Non-Executive Director at Glenmark Pharmaceuticals Ltd. He has over 35 years of work experience and was the Executive Director and Chief Financial Officer of Glenmark untill 2016. He led the Finance, Legal and IT functions and with his strong Finance background, he contributed significantly to the growth story of Glenmark.

Sridhar Gorthi

Mr. Sridhar Gorthi serves as Non-Executive Independent Director of the Company. Mr. Gorthi is a partner in the Mumbai office of Trilegal. His areas of expertise include M&A, joint ventures, private equity and venture capital. Apart from representing several international clients on M&A in India, he has also advised Indian companies about outbound M&A transactions in jurisdictions, such as the UK, the US, South Africa, Argentina, Indonesia and Sri Lanka.

Devendra Mehta

Shri. Devendra Raj Mehta serves as Non-Executive Independent Director of Glenmark Pharmaceuticals Ltd. Mr. Mehta was a civil servant for almost four decades with experience in administration and management of public affairs. He joined the IAS in 1961 and has held positions in the Government of Rajasthan and in the Government of India. He has served as the Chairman of SEBI, the Deputy Governor of the RBI and the Director General of Foreign Trade, Ministry of Commerce, Government of India.

Bernard Munos

Mr. Bernard Munos serves as Non-Executive Independent Director of Glenmark Pharmaceuticals Ltd. Mr. Munos advises organizations on being better innovators. He serves on the advisory council of the National Center for Advancing Translational Sciences (NCATS), is a member of the National Academy of Medicine’s Forum on Drug R&D and Translation, and is an advisor to the journal, Science Translational Medicine. His research on pharmaceutical innovation has been published in Nature and Science, and profiled by Forbes magazine.

Sona Ramasastry

Ms. Sona Saira Ramasastry serves as Non-Executive Independent Director of the Company. Ms. Ramasastry has over 20 years of experience in the Life Sciences industry, successfully building companies as an advisor, board member and operational executive. She is the Founder and Managing Partner of Life Sciences Advisory, LLC. Ms. Ramasastry’s accomplishments include being named as ‘Top Life Sciences Advisor’ by Acquisition International and CorporateLiveWire.

Brian Tempest

Dr. Brian William Tempest serves as Non-Executive Independent Director of Glenmark Pharmaceuticals Ltd. Dr. Tempest has been working with the pharmaceutical industry for the last four decades. He has managed healthcare businesses in North America, South America, Europe, Africa, the Middle East, Australia, China, Japan and India. He is the editor of the Journal of Generic Medicines. He is also a Non-Executive Director on the Governance Board of the United Nations Patent Pool.

Basic Compensation

Name Fiscal Year Total

Glenn Saldanha

122,350,000

V. S. Mani

51,500,000

Harish Kuber

3,960,000

Cherylann Pinto

45,210,000

Blanche Saldanha

400,000

Dipankar Bhattacharjee

--

Rajesh Desai

1,600,000

Sridhar Gorthi

400,000

Devendra Mehta

1,600,000

Bernard Munos

400,000

Sona Ramasastry

400,000

Brian Tempest

400,000
As Of  31 Mar 2020